Form 4: AtriCure Executive Justin Noznesky Sells 1,500 Shares Under 10b5-1 Plan

AtriCure's Chief Marketing & Strategy Officer, Justin J. Noznesky, sold 1,500 shares of common stock on April 1, 2024, at a price of $30.39 per share, according to a Form 4 filing with the SEC.

Summary

• Justin J. Noznesky, Chief Marketing & Strategy Officer of AtriCure, Inc., reported a transaction involving the company's common stock.
• On April 1, 2024, Noznesky sold 1,500 shares of AtriCure common stock at a price of $30.39 per share.
• The sale was executed under a pre-arranged 10b5-1 trading plan adopted on December 12, 2023.
• Following the transaction, Noznesky directly owns 72,784 shares of AtriCure common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. The sale was pre-planned under a 10b5-1 trading plan, suggesting no immediate cause for concern or excitement.

Industry Context

Sales by company executives are a normal part of corporate governance. The fact that the sale was executed under a 10b5-1 trading plan suggests that the decision to sell was made in advance and not based on any inside information at the time of the sale.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but the pre-planned nature of the sale mitigates potential concerns.

Key Dates